NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
View Patent ↗Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.
1. A method of treating, reducing, or ameliorating a renal injury selected from the group consisting of an ischemic renal injury and an ischemic-reperfusion renal injury to a kidney, comprising the step of administering exogenous neutrophil gelatinase-associated lipocalin (NGAL) in an amount effective to treat, reduce or ameliorate the renal injury to the kidney.
2. The method according to claim 1 , wherein the kidney is transplanted into a patient, and the NGAL is administered to a cadaverous or a living donor kidney prior to transplant of the kidney into the patient.
3. The method according to claim 2 , wherein NGAL is administered to the patient prior to, during, or following transplant of the kidney.
4. The method according to claim 2 wherein the exogenous NGAL is administered using an organ preservation solution comprising NGAL.
5. The method according to claim 4 wherein the exogenous NGAL is administered using an organ preservation solution comprising at least 0.1 μg NGAL/μL solution.
6. The method according to claim 5 wherein the organ preservation solution comprises at least 1 μg NGAL/μL solution.
7. The method according to claim 5 wherein the organ preservation solution further comprises a siderophore.
8. The method according to claim 7 , wherein the NGAL and siderophore are co-administered as a complexed compound of NGAL and the siderophore.
9. The method according to claim 1 , wherein the NGAL is administered intravenously or parenterally.
10. The method according to claim 1 , wherein the renal injury is associated with conditions, treatments, therapies, or diseases that predispose a patient to the ischemic renal injury.
11. The method according to claim 1 , wherein the renal injury results from a condition, treatment, or therapy selected from the group consisting of contrast agent treatment, antibody treatment, antibiotic treatment, organ transplant, kidney transplant, cadaveric kidney transplant, cardiac treatment, cardiac treatment after surgery, and central nervous system treatment.
12. The method according to claim 1 , wherein the renal injury results from a condition, treatment, therapy, or disease selected from the group consisting of infection, bacterial infection, kidney disease, ischemic-reperfusion injury, cardiac reperfusion injury, cardiopulmonary bypass surgery, open heart surgery, and abdominal surgery.
13. The method according to claim 1 , wherein the injury is an ischemia-reperfusion injury to a kidney, and NGAL administration ameliorates a reduction in kidney function.
14. The method according to claim 1 , further comprising the step of administering to the patient a siderophore in an amount effective to enhance the treating, reducing, or ameliorating of the renal injury by NGAL.
15. The method according to claim 14 , wherein NGAL and the siderophore are co-administered as a complexed compound of NGAL and the siderophore.
16. The method according to claim 1 wherein the step of administering comprises administering a composition comprising NGAL, in an amount effective to treat, reduce, or ameliorate the renal injury to the kidney.
17. The method according to claim 16 , wherein the composition comprises at least 10 microgram NGAL per 100 microliter of composition.
18. The method according to claim 17 , wherein the composition further comprising a siderophore.
19. The method according to claim 18 , wherein the NGAL and siderophore are co-administered as a complexed compound of NGAL and the siderophore.
20. The method according to claim 1 wherein the renal injury is an ischemic-reperfusion injury to a kidney transplant in a patient, and wherein the step of administering NGAL comprises administering the exogenous NGAL to (i) the kidney transplant, (ii) a donor of the kidney transplant, or (iii) both (i) and (ii), in an amount of NGAL effective to reduce or ameliorate delayed graft function (DGF) or rejection of the kidney transplant.
21. The method according to claim 20 wherein the kidney transplant is a cadaveric or living donor kidney.
22. The method according to claim 20 , further comprising the step of administering to the patient a siderophore in an amount effective to enhance the reducing or ameliorating of the ischemic-reperfusion injury effected by NGAL.
23. The method according to claim 22 , wherein NGAL and the siderophore are co-administered as a complexed compound of NGAL and the siderophore.